OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel.
| Revenue (Most Recent Fiscal Year) | $713.10M |
| Net Income (Most Recent Fiscal Year) | $-53.22M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.64 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.84 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 19.92 |
| Pre-Tax Margin (Trailing 12 Months) | -22.97% |
| Net Margin (Trailing 12 Months) | -26.68% |
| Return on Equity (Trailing 12 Months) | -13.17% |
| Return on Assets (Trailing 12 Months) | -8.28% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.41 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.02 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.25 |
| Inventory Turnover (Trailing 12 Months) | 7.26 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.00 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.19 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.08 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.25 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 793.78M |
| Free Float | 399.35M |
| Market Capitalization | $1.09B |
| Average Volume (Last 20 Days) | 3.04M |
| Beta (Past 60 Months) | 1.19 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 49.69% |
| Percentage Held By Institutions (Latest 13F Reports) | 64.63% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |